A novel drug response score more accurately predicts renoprotective drug effects than existing renal risk scores

por Idzerda, Nienke M. A., Tye, Sok Cin, de Zeeuw, Dick, Heerspink, Hiddo J. L.
Publicado 2021

Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials

por Idzerda, Nienke M A, Pena, Michelle J, Parving, Hans-Henrik, de Zeeuw, Dick, Heerspink, Hiddo J L
Publicado 2019

Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers

por Idzerda, Nienke M A, Stefansson, Bergur V, Pena, Michelle J, Sjostrom, David C, Wheeler, David C, Heerspink, Hiddo J L
Publicado 2019

Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL

por Idzerda, Nienke M. A., Clegg, Lindsay E., Hernandez, Adrian F., Bakris, George, Penland, Robert C., Boulton, David W., Bethel, M. Angelyn, Holman, Rury R., Heerspink, Hiddo J. L.
Publicado 2020

N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) predicts the cardio‐renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk

por Idzerda, Nienke M. A., Persson, Frederik, Pena, Michelle J., Brenner, Barry M., Brunel, Patrick, Chaturvedi, Nish, McMurray, John J., Parving, Hans‐Henrik, de Zeeuw, Dick, Heerspink, Hiddo J. L.
Publicado 2018